LifeVantage Corp. (LFVN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1247331,
    "name": "LifeVantage Corp.",
    "stock_name": "LifeVantage Corp.",
    "full_name": "LifeVantage Corp.",
    "name_url": "stocks-analysis/lifevantage-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "6.97",
    "chg": 0.49,
    "chgp": "7.56%",
    "dir": 1,
    "prev_price": "6.48",
    "mcapval": "145.19",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2310,
    "indexname": "S&P 500",
    "isin": "US53222K2050",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "285.99 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/lifevantage-corp-1247331-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "LifeVantage Corp. Stock Plummets to New 52-Week Low of $6.96",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lifevantage-corp-stock-plummets-to-new-52-week-low-of-696-3673989",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/LifeVantageCorp_priceRelatedfactors_3673989.png",
        "date": "2025-11-05 16:30:55",
        "description": "LifeVantage Corp. has reached a new 52-week low, reflecting a decline in stock performance compared to the broader market. The company, with a market capitalization of USD 145 million, reported a net profit growth of 83.16% in the first half of the year and maintains significant institutional interest."
      },
      {
        "title": "LifeVantage Corp. Stock Hits New 52-Week Low at USD 7.10",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lifevantage-corp-stock-hits-new-52-week-low-at-usd-710-3671461",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/LifeVantageCorp_priceRelatedfactors_3671461.png",
        "date": "2025-11-04 17:46:30",
        "description": "LifeVantage Corp. has hit a new 52-week low, experiencing a significant stock price decline over the past year, contrasting with broader market trends. Despite this, the company reported an 83.16% increase in net profit for the first half of the year and maintains a strong return on equity."
      },
      {
        "title": "LifeVantage Corp. Stock Hits New 52-Week Low at $8.05",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lifevantage-corp-stock-hits-new-52-week-low-at-805-3661888",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LifeVantageCorp_priceRelatedfactors_3661888.png",
        "date": "2025-10-31 16:02:11",
        "description": "LifeVantage Corp., a microcap in the Pharmaceuticals & Biotechnology sector, recently hit a 52-week low, reflecting a challenging year with a significant decline in stock performance. Despite this, the company reports strong financial metrics, including a high return on equity and substantial net profit growth, while facing long-term operating profit challenges."
      },
      {
        "title": "LifeVantage Corp. Stock Hits New 52-Week Low at USD 8.10",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lifevantage-corp-stock-hits-new-52-week-low-at-usd-810-3659071",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LifeVantageCorp_priceRelatedfactors_3659071.png",
        "date": "2025-10-30 18:19:42",
        "description": "LifeVantage Corp. has reached a new 52-week low while experiencing a significant increase in net profit, which rose by 83.16% in the first half of the year. The company maintains a strong return on equity and low debt-to-equity ratio, despite facing long-term growth challenges."
      },
      {
        "title": "LifeVantage Corp. Experiences Valuation Adjustment Amid Mixed Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lifevantage-corp-valuation-grade-downgraded-from-very-attractive-to-attractive-3649138",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LifeVantageCorp_valuationdot_3649138.png",
        "date": "2025-10-27 16:11:02",
        "description": "LifeVantage Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has seen a recent valuation adjustment, with its stock price at $8.67. Over the past year, the company has faced challenges, posting a -33.20% return. Key metrics indicate effective resource management but raise questions about market valuation compared to peers."
      },
      {
        "title": "LifeVantage Corp. Stock Hits 52-Week Low at $8.49 Amid Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lifevantage-corp-stock-hits-52-week-low-at-849-amid-decline-3641253",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/LifeVantageCorp_priceRelatedfactors_3641253.png",
        "date": "2025-10-23 17:02:49",
        "description": "LifeVantage Corp. has reached a new 52-week low, reflecting its struggles in the Pharmaceuticals & Biotechnology sector. Despite a one-year return of -28.62%, the company reports a strong return on equity of 28.30% and an 83.16% increase in net profit for the first half of the year."
      },
      {
        "title": "Is LifeVantage Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-lifevantage-corp-overvalued-or-undervalued-3637533",
        "imagepath": "",
        "date": "2025-10-21 12:04:13",
        "description": "As of 17 October 2025, the valuation grade for LifeVantage Corp. has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company appears undervalued, supported by a P/E ratio of 17, a PEG ratio of 0.11, and an EV to EBITDA ratio of 8.48, which are significantly more favorable compared to its peers. For instance, Chromadex Corp. has a much higher P/E of 39.82, while USANA Health Sciences, Inc. shows an EV to EBITDA of 4.73, highlighting LifeVantage's relative attractiveness in the market.\n\nDespite recent underperformance, with a year-to-date return of -49.74% compared to the S&P 500's 13.30%, LifeVantage's strong fundamentals, including a remarkable ROCE of 96.19% and a solid ROE of 26.91%, suggest that it may be poised for recovery. Overall, the combination of favorable valuation ratios and strong operational metrics supports the conclusion that LifeVantage Corp..."
      },
      {
        "title": "Is LifeVantage Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-lifevantage-corp-overvalued-or-undervalued-3634400",
        "imagepath": "",
        "date": "2025-10-20 12:21:41",
        "description": "As of 17 October 2025, the valuation grade for LifeVantage Corp. moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears undervalued, supported by a P/E ratio of 17, a PEG ratio of 0.11, and an EV to EBITDA ratio of 8.48, all of which suggest that the stock is trading at a discount compared to its growth potential. In comparison to peers, Chromadex Corp. has a significantly higher P/E ratio of 39.82, while USANA Health Sciences, Inc. is considered expensive with a P/E of 16.23.\n\nDespite recent challenges reflected in the stock's performance, with a year-to-date return of -49.74% compared to the S&P 500's 13.30%, the long-term outlook remains promising, as evidenced by a 3-year return of 130.63% against the benchmark's 81.19%. This divergence in performance highlights the potential for recovery and growth in LifeVantage Corp...."
      },
      {
        "title": "Is LifeVantage Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-lifevantage-corp-overvalued-or-undervalued-3631941",
        "imagepath": "",
        "date": "2025-10-19 11:59:19",
        "description": "As of 17 October 2025, the valuation grade for LifeVantage Corp. has moved from attractive to very attractive, indicating a stronger outlook for the company. Based on the analysis, LifeVantage appears to be undervalued. The P/E ratio stands at 17, which is significantly lower than the peer Chromadex Corp. at 39.82, while the PEG ratio of 0.11 suggests that the stock is undervalued relative to its growth potential. Additionally, the EV to EBITDA ratio of 8.48 further supports this undervaluation compared to its peers.\n\nIn terms of peer comparison, LifeVantage's P/E ratio of 14.81 is favorable when compared to USANA Health Sciences, which has a P/E of 16.23, indicating a better valuation relative to its earnings. Despite recent stock performance showing a decline of 49.74% year-to-date compared to a 13.30% gain in the S&P 500, the long-term perspective is promising, with a 3-year return of 130.63%, outperform..."
      }
    ],
    "total": 25,
    "sid": "1247331",
    "stock_news_url": "https://www.marketsmojo.com/news/lifevantage-corp-1247331"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

LifeVantage Corp. Stock Plummets to New 52-Week Low of $6.96

2025-11-05 16:30:55

LifeVantage Corp. has reached a new 52-week low, reflecting a decline in stock performance compared to the broader market. The company, with a market capitalization of USD 145 million, reported a net profit growth of 83.16% in the first half of the year and maintains significant institutional interest.

LifeVantage Corp. Stock Hits New 52-Week Low at USD 7.10

2025-11-04 17:46:30

LifeVantage Corp. has hit a new 52-week low, experiencing a significant stock price decline over the past year, contrasting with broader market trends. Despite this, the company reported an 83.16% increase in net profit for the first half of the year and maintains a strong return on equity.

LifeVantage Corp. Stock Hits New 52-Week Low at $8.05

2025-10-31 16:02:11

LifeVantage Corp., a microcap in the Pharmaceuticals & Biotechnology sector, recently hit a 52-week low, reflecting a challenging year with a significant decline in stock performance. Despite this, the company reports strong financial metrics, including a high return on equity and substantial net profit growth, while facing long-term operating profit challenges.

LifeVantage Corp. Stock Hits New 52-Week Low at USD 8.10

2025-10-30 18:19:42

LifeVantage Corp. has reached a new 52-week low while experiencing a significant increase in net profit, which rose by 83.16% in the first half of the year. The company maintains a strong return on equity and low debt-to-equity ratio, despite facing long-term growth challenges.

LifeVantage Corp. Experiences Valuation Adjustment Amid Mixed Performance Metrics

2025-10-27 16:11:02

LifeVantage Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has seen a recent valuation adjustment, with its stock price at $8.67. Over the past year, the company has faced challenges, posting a -33.20% return. Key metrics indicate effective resource management but raise questions about market valuation compared to peers.

LifeVantage Corp. Stock Hits 52-Week Low at $8.49 Amid Decline

2025-10-23 17:02:49

LifeVantage Corp. has reached a new 52-week low, reflecting its struggles in the Pharmaceuticals & Biotechnology sector. Despite a one-year return of -28.62%, the company reports a strong return on equity of 28.30% and an 83.16% increase in net profit for the first half of the year.

Is LifeVantage Corp. overvalued or undervalued?

2025-10-21 12:04:13

As of 17 October 2025, the valuation grade for LifeVantage Corp. has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company appears undervalued, supported by a P/E ratio of 17, a PEG ratio of 0.11, and an EV to EBITDA ratio of 8.48, which are significantly more favorable compared to its peers. For instance, Chromadex Corp. has a much higher P/E of 39.82, while USANA Health Sciences, Inc. shows an EV to EBITDA of 4.73, highlighting LifeVantage's relative attractiveness in the market. Despite recent underperformance, with a year-to-date return of -49.74% compared to the S&P 500's 13.30%, LifeVantage's strong fundamentals, including a remarkable ROCE of 96.19% and a solid ROE of 26.91%, suggest that it may be poised for recovery. Overall, the combination of favorable valuation ratios and strong operational metrics supports the conclusion that LifeVantage Corp...

Is LifeVantage Corp. overvalued or undervalued?

2025-10-20 12:21:41

As of 17 October 2025, the valuation grade for LifeVantage Corp. moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears undervalued, supported by a P/E ratio of 17, a PEG ratio of 0.11, and an EV to EBITDA ratio of 8.48, all of which suggest that the stock is trading at a discount compared to its growth potential. In comparison to peers, Chromadex Corp. has a significantly higher P/E ratio of 39.82, while USANA Health Sciences, Inc. is considered expensive with a P/E of 16.23. Despite recent challenges reflected in the stock's performance, with a year-to-date return of -49.74% compared to the S&P 500's 13.30%, the long-term outlook remains promising, as evidenced by a 3-year return of 130.63% against the benchmark's 81.19%. This divergence in performance highlights the potential for recovery and growth in LifeVantage Corp....

Is LifeVantage Corp. overvalued or undervalued?

2025-10-19 11:59:19

As of 17 October 2025, the valuation grade for LifeVantage Corp. has moved from attractive to very attractive, indicating a stronger outlook for the company. Based on the analysis, LifeVantage appears to be undervalued. The P/E ratio stands at 17, which is significantly lower than the peer Chromadex Corp. at 39.82, while the PEG ratio of 0.11 suggests that the stock is undervalued relative to its growth potential. Additionally, the EV to EBITDA ratio of 8.48 further supports this undervaluation compared to its peers. In terms of peer comparison, LifeVantage's P/E ratio of 14.81 is favorable when compared to USANA Health Sciences, which has a P/E of 16.23, indicating a better valuation relative to its earnings. Despite recent stock performance showing a decline of 49.74% year-to-date compared to a 13.30% gain in the S&P 500, the long-term perspective is promising, with a 3-year return of 130.63%, outperform...

View All News